1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrakis(methylenephosphonic acid) has been researched along with holmium in 7 studies
| Studies (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrakis(methylenephosphonic acid)) | Trials (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrakis(methylenephosphonic acid)) | Recent Studies (post-2010) (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrakis(methylenephosphonic acid)) | Studies (holmium) | Trials (holmium) | Recent Studies (post-2010) (holmium) |
|---|---|---|---|---|---|
| 25 | 4 | 8 | 1,135 | 107 | 542 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 5 (71.43) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Avila, MJ; Cain, GR; Fisher, P; Hornoff, W; Kawakami, TG; Moore, P; Parks, NJ; Raaka, SD; Seibert, JA; White, R | 1 |
| Bensinger, W; Durack, LD; Eary, JF; Fritzberg, A; Rajendran, JG; Vernon, C | 1 |
| Alexanian, R; Bensinger, W; Breitz, H; Champlin, R; Eary, J; Ghalie, R; Giralt, S; Goodman, M; Holmberg, L; Maloney, D; Podoloff, D; Rajandran, J; Weber, D; Wendt, R | 1 |
| Bouchet, L; Breitz, H; Stabin, M; Wendt, R; Wessels, B | 1 |
| Breitz, HB; Delpassand, E; Durack, L; Eary, JF; Erwin, WD; Martin, W; Meredith, RF; Rajendran, JG; Shen, S; Stabin, MS; Wendt, RE | 1 |
| Aleman, A; Alexanian, R; Breitz, H; Champlin, R; Christoforidou, AV; Giralt, S; Mendoza, F; Podoloff, D; Qazilbash, M; Roden, L; Saliba, RM; Weber, D; Wendt, R; Williams, P | 1 |
| Afarideh, H; Vaez-Tehrani, M; Yousefnia, H; Zolghadri, S | 1 |
4 trial(s) available for 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrakis(methylenephosphonic acid) and holmium
| Article | Year |
|---|---|
High-dose 166Ho-DOTMP in myeloablative treatment of multiple myeloma: pharmacokinetics, biodistribution, and absorbed dose estimation.
Topics: Antineoplastic Agents, Alkylating; Bone Marrow Purging; Female; Holmium; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Organophosphorus Compounds; Radioisotopes; Radiometry; Radiotherapy Dosage; Tissue Distribution | 2002 |
166Ho-DOTMP plus melphalan followed by peripheral blood stem cell transplantation in patients with multiple myeloma: results of two phase 1/2 trials.
Topics: Adult; Aged; Bone and Bones; Combined Modality Therapy; Cystitis; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Hemorrhage; Holmium; Humans; Incidence; Kidney Diseases; Male; Middle Aged; Multiple Myeloma; Myelodysplastic Syndromes; Organophosphorus Compounds; Radioisotopes; Renal Circulation; Survival Rate; Thrombosis; Tissue Distribution; Treatment Outcome | 2003 |
Dosimetry of high dose skeletal targeted radiotherapy (STR) with 166Ho-DOTMP.
Topics: Antineoplastic Agents, Alkylating; Cohort Studies; Combined Modality Therapy; Holmium; Humans; Maximum Tolerated Dose; Melphalan; Multiple Myeloma; Muscle, Skeletal; Organophosphorus Compounds; Radioisotopes; Radiometry; Radiotherapy Dosage; Tissue Distribution | 2003 |
166Ho-DOTMP radiation-absorbed dose estimation for skeletal targeted radiotherapy.
Topics: Aged; Body Burden; Bone Neoplasms; Female; Holmium; Humans; Male; Middle Aged; Multiple Myeloma; Organophosphorus Compounds; Radioisotopes; Radiopharmaceuticals; Radiotherapy; Radiotherapy Dosage; Relative Biological Effectiveness; Reproducibility of Results; Sensitivity and Specificity; Whole-Body Counting | 2006 |
3 other study(ies) available for 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrakis(methylenephosphonic acid) and holmium
| Article | Year |
|---|---|
Bone marrow transplantation in dogs after radio-ablation with a new Ho-166 amino phosphonic acid bone-seeking agent (DOTMP).
Topics: Animals; Bone and Bones; Bone Marrow Transplantation; Chelating Agents; Dogs; Hematopoiesis; Holmium; Organophosphonates; Organophosphorus Compounds; Radioisotopes; Tissue Distribution | 1993 |
Results of a retrospective single institution analysis of targeted skeletal radiotherapy with (166)Holmium-DOTMP as conditioning regimen for autologous stem cell transplant for patients with multiple myeloma. Impact on transplant outcomes.
Topics: Adult; Aged; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Holmium; Humans; Male; Middle Aged; Multiple Myeloma; Organophosphorus Compounds; Radioisotopes; Retrospective Studies; Survivors; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2007 |
Estimation of human absorbed dose for (166)Ho-PAM: comparison with (166)Ho-DOTMP and (166)Ho-TTHMP.
Topics: Absorption, Radiation; Animals; Bone Marrow; Coordination Complexes; Holmium; Humans; Multiple Myeloma; Organ Specificity; Organometallic Compounds; Organophosphonates; Organophosphorus Compounds; Radiation Dosage; Radioisotopes; Rats; Tissue Distribution | 2016 |